Mercer Global Advisors Inc. ADV acquired a new position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 19,904 shares of the company’s stock, valued at approximately $126,000.
Several other large investors have also recently made changes to their positions in the stock. Bleakley Financial Group LLC acquired a new position in shares of ImmunityBio in the 1st quarter valued at about $58,000. Lazard Asset Management LLC boosted its position in shares of ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock worth $68,000 after buying an additional 6,593 shares during the period. Copperwynd Financial LLC acquired a new stake in ImmunityBio in the fourth quarter valued at $79,000. Axxcess Wealth Management LLC acquired a new position in ImmunityBio in the first quarter valued at approximately $85,000. Finally, Brookstone Capital Management acquired a new position in ImmunityBio in the first quarter valued at $100,000. 8.58% of the stock is owned by institutional investors.
ImmunityBio Stock Performance
IBRX stock opened at $3.60 on Wednesday. The firm has a market cap of $2.49 billion, a P/E ratio of -3.30 and a beta of 1.02. The stock has a 50-day simple moving average of $4.07 and a 200-day simple moving average of $5.59. ImmunityBio, Inc. has a 1 year low of $1.25 and a 1 year high of $10.53.
Analyst Ratings Changes
Separately, Piper Sandler decreased their price target on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a research note on Monday, August 19th.
View Our Latest Analysis on IBRX
ImmunityBio Company Profile
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Articles
- Five stocks we like better than ImmunityBio
- Using the MarketBeat Stock Split Calculator
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What Are Some of the Best Large-Cap Stocks to Buy?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Want to see what other hedge funds are holding IBRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunityBio, Inc. (NASDAQ:IBRX – Free Report).
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.